Insmed (0JAV) Share Forecast & Price Target
0JAV Analyst Ratings
Strong Buy
20Buy1Hold0Sell
Based on 21 analysts giving stock ratings to Insmed in the past 3 months
0JAV Stock 12 Month Forecast
Average Price Target
$194.63â–²(72.68% Upside)Based on 21 Wall Street analysts offering 12 month price targets for Insmed in the last 3 months. The average price target is $194.63 with a high forecast of $243.00 and a low forecast of $154.00. The average price target represents a 72.68% change from the last price of $112.71.
Past 12 Months12 Month ForecastDec2025Sep2026
High$243.00
Average$194.63
Low$154.00
Highest Price TargetHighest$243.00Average Price Target$194.63Lowest Price TargetLowest$154.00
Detailed List of Analyst Forecasts​
Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| Ashwani Verma | UBS | $172 | buy | 52.60%Upside | Reiterated | 10/30/26 | ||
| Conor MacKay | BMO Capital | $192 | buy | 70.34%Upside | Reiterated | 10/30/26 | ||
| Andrea Newkirk | Goldman Sachs | $188→$194 | buy | 72.12%Upside | Reiterated | 10/30/26 | ||
| Maxwell Skor | Morgan Stanley | $213 | buy | 88.98%Upside | Assigned | 10/30/26 | ||
| Graig Suvannavejh | Mizuho Securities | $195→$154 | buy | 36.63%Upside | Reiterated | 10/29/26 | ||
| Adam Walsh | Roth MKM | $198→$204 | buy | 80.99%Upside | Reiterated | 10/29/26 | ||
| Leonid Timashev | RBC Capital | $195 | buy | 73.01%Upside | Assigned | 10/29/26 | ||
| Andrew Fein | H.C. Wainwright | $220 | buy | 95.19%Upside | Reiterated | 10/27/26 | ||
| Tiago Fauth | Raymond James | $187→$173 | buy | 53.49%Upside | Reiterated | 10/20/26 | ||
| Benjamin Burnett | Wells Fargo | $169 | buy | 49.94%Upside | Assigned | 10/13/26 | ||
| Andy Chen | Wolfe Research | ― | hold | ― | Downgraded | 10/12/26 | ||
| Jason Zemansky | Bank of America Securities | $207 | buy | 83.65%Upside | Reiterated | 10/12/26 | ||
| Eliana Merle | Barclays | $237→$207 | buy | 83.65%Upside | Reiterated | 09/30/26 | ||
| Jessica Fye | J.P. Morgan | $175 | buy | 55.26%Upside | Reiterated | 09/28/26 | ||
| Danielle Brill | Truist Financial | $185→$195 | buy | 73.01%Upside | Reiterated | 08/10/26 |
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| Ashwani Verma | 10/30/26 | $172 | buy | 52.60%Upside | Reiterated | UBS | ||
| Conor MacKay | 10/30/26 | $192 | buy | 70.34%Upside | Reiterated | BMO Capital | ||
| Andrea Newkirk | 10/30/26 | $188→$194 | buy | 72.12%Upside | Reiterated | Goldman Sachs | ||
| Maxwell Skor | 10/30/26 | $213 | buy | 88.98%Upside | Assigned | Morgan Stanley | ||
| Graig Suvannavejh | 10/29/26 | $195→$154 | buy | 36.63%Upside | Reiterated | Mizuho Securities | ||
| Adam Walsh | 10/29/26 | $198→$204 | buy | 80.99%Upside | Reiterated | Roth MKM | ||
| Leonid Timashev | 10/29/26 | $195 | buy | 73.01%Upside | Assigned | RBC Capital | ||
| Andrew Fein | 10/27/26 | $220 | buy | 95.19%Upside | Reiterated | H.C. Wainwright | ||
| Tiago Fauth | 10/20/26 | $187→$173 | buy | 53.49%Upside | Reiterated | Raymond James | ||
| Benjamin Burnett | 10/13/26 | $169 | buy | 49.94%Upside | Assigned | Wells Fargo | ||
| Andy Chen | 10/12/26 | ― | hold | ― | Downgraded | Wolfe Research | ||
| Jason Zemansky | 10/12/26 | $207 | buy | 83.65%Upside | Reiterated | Bank of America Securities | ||
| Eliana Merle | 09/30/26 | $237→$207 | buy | 83.65%Upside | Reiterated | Barclays | ||
| Jessica Fye | 09/28/26 | $175 | buy | 55.26%Upside | Reiterated | J.P. Morgan | ||
| Danielle Brill | 08/10/26 | $185→$195 | buy | 73.01%Upside | Reiterated | Truist Financial |
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Best Analysts Covering Insmed
3 Months
Success Rate13/18 ratings generated profit
72%
Average Return
+41.83%
Copying Tiago Fauth's trades and holding each position for 3 Months would result in 72.22% of your transactions generating a profit, with an average return of +41.83% per trade.
1 Year
Success Rate16/18 ratings generated profit
89%
Average Return
+79.71%
Copying Tiago Fauth's trades and holding each position for 1 Year would result in 88.89% of your transactions generating a profit, with an average return of +79.71% per trade.
2 Years
Success Rate16/18 ratings generated profit
89%
Average Return
+174.42%
Copying Tiago Fauth's trades and holding each position for 2 Years would result in 88.89% of your transactions generating a profit, with an average return of +174.42% per trade.
0JAV Analyst Recommendation Trends
| Rating | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 |
|---|---|---|---|---|---|
| Strong Buy | 33 | 51 | 46 | 42 | 41 |
| Buy | 19 | 8 | 14 | 15 | 12 |
| Hold | 0 | 0 | 0 | 0 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 52 | 59 | 60 | 57 | 54 |
In the current month, 0JAV has received 53 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. 0JAV average Analyst price target in the past 3 months is 194.63.
0JAV Financial Forecast
High$0.16
Consensus$-0.32
Low$-0.89
0JAV Earnings Forecast
Next quarter’s earnings estimate for 0JAV is -$0.32 with a range of -$0.89 to $0.16. The previous quarter’s EPS was -$0.46. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
High$648M
Consensus$597M
Low$558M
0JAV Sales Forecast
Next quarter’s sales forecast for 0JAV is $597.35M with a range of $558.10M to $647.66M. The previous quarter’s sales results were $524.43M. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.
0JAV Stock Forecast FAQ
What is GB:0JAV’s average 12-month price target, according to analysts?
Based on analyst ratings, Insmed’s 12-month average price target is $194.63.
What is GB:0JAV’s upside potential, based on the analysts’ average price target?
Insmed has 72.68% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Insmed a Buy, Sell or Hold?
Insmed has a consensus rating of Strong Buy, which is based on 20 buy ratings, 1 hold ratings and 0 sell ratings.
What is Insmed’s share price target?
The average share price target for Insmed is $194.63. This is based on 21 Wall Street analysts’ 12-month price targets, issued in the past 3 months. The highest analyst share price target is $243.00, and the lowest forecast is $154.00. The average share price target represents a 72.68% increase from the current price of $112.713.
What do analysts say about Insmed?
Insmed’s analyst rating consensus is a Strong Buy. This is based on the ratings of 21 Wall Street analysts.
How can I buy shares of Insmed?
To buy shares of GB:0JAV, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.